Basal Cell Carcinoma Clinical Trials
Oncologists conduct basal cell carcinoma clinical trials to determine the benefits of promising new treatments. These studies also allow patients to access some of the newest, most innovative therapies for basal cell carcinoma, long before those treatments are made available in other settings.
Moffitt Cancer Center’s Cutaneous Oncology Program has one of the most robust clinical trials programs in the region. As a National Cancer Institute-designated Comprehensive Cancer Center, we have tested novel skin cancer treatments such as:
- Intralesional therapy, a treatment in which anti-cancer medications are injected directly into the tumor site. In past studies, this treatment produced notable tumor shrinkage in more than half of the participants.
- Adoptive cell therapy, a treatment in which tumor-specific T-cells are administered to a patient, with the intent of triggering the body’s natural immune response. Moffitt is one of just three cancer centers in the entire nation to have clinical protocol for using T-cell therapy to treat skin cancer.
- Immunotherapy, another treatment that is designed to program the body’s immune system to attack the tumor. This therapy has been the subject of many promising clinical trials for other cancers, and its effectiveness for skin cancer is currently being investigated.
Florida's First NCI-designated Comprehensive Cancer Center
Recognized for its scientific excellence, Moffitt is the state's longest-established National Cancer Institute-designated Comprehensive Cancer Center.
These trials may be especially beneficial for patients with difficult-to-treat cancers, such as basal cell carcinoma that has metastasized to other parts of the body. Even for non-metastatic carcinomas, which are highly responsive to conventional therapies, clinical trials can help researchers determine the best order in which to prescribe certain treatments (for example, surgery before radiation therapy or vice versa.)
Patients can participate in Moffitt Cancer Center’s basal cell carcinoma clinical trials without requesting a referral from their primary physicians. To learn which of our trials are most appropriate for your needs and whether you may qualify, call 1-813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.
-
Clinical Trials
CLINICAL TRIAL 19868
First in Human Phase I Study of 225Actinium-DOTA-Ahx-MC1RL (225Ac-MTI-201) in Metastatic Melanoma
Condition: Cutaneous
Intervention: 225Ac-MTI-201 ()
CLINICAL TRIAL 20490
Keystroke: A Randomized Phase II Study of Pembrolizumab (Keytruda) Plus Stereotactic Re-irradiation versus SBRT Alone For Locoregionally Recurrent or Second Primary Head and Neck Carcinoma
Condition: Head & Neck
Intervention: Pembrolizumab (Keytruda)
CLINICAL TRIAL 20494
A Phase II Study of High Dose Bolus IL2 in Combination with Low Dose Ipilimumab Followed Sequentially by Nivolumab in Patients with Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy
Condition: Cutaneous
Intervention: Aldesleukin (Interleukin-2); BMS-936558 (Nivolumab); IL-2 (Interleukin-2); Interleukin-2 (); Ipilimumab (); Nivolumab (Opdivo); Proleukin (Interleukin-2); Yervoy (Ipilimumab)
CLINICAL TRIAL 20641
A Randomized Pilot Trial of Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib and Binimetinib in Advanced Melanoma
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); Binimetinib (); Encorafenib (); Nivolumab (Opdivo); Not Applicable ()
CLINICAL TRIAL 20731
Phase 2 Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma
Condition: Cutaneous
Intervention: Afatinib (); BIBW 2992 (Afatinib)
CLINICAL TRIAL 21112
Phase 2 Study of Axitinib + Ipilimumab in Advanced Melanoma
Condition: Cutaneous
Intervention: Ipilimumab (); Yervoy (Ipilimumab); axitinib (AG-013736)
CLINICAL TRIAL 21239
Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); Ipilimumab (); Nivolumab (Opdivo); Sargramostim (); Yervoy (Ipilimumab)
CLINICAL TRIAL 21731
A Phase II Trial of Olaparib in Combination with Pembrolizumab for Advanced Uveal Melanoma
Condition: Cutaneous
Intervention: Olaparib (Lynparza); Pembrolizumab (Keytruda)
CLINICAL TRIAL 23460
A Multicenter Phase I/Ib Dose Escalation Study of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Patients with Selected Advanced or Metastatic Solid Tumors
Condition: Cutaneous
Intervention: Pembrolizumab (Keytruda)
CLINICAL TRIAL 21996
An Open-Label, Multicenter, Phase 1b/2 Study of RP1 in Solid Organ Transplant Recipients with Advanced Cutaneous Malignancies
Condition: Cutaneous
Intervention: RP1 ()
CLINICAL TRIAL 21997
Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma
Condition: Cutaneous
Intervention: Not Applicable (); Vismodegib (Erivedge)
CLINICAL TRIAL 22079
A Phase 1/2, Open-Label Study of PD-1 Knockout Tumor-Infiltrating Lymphocytes (IOC-4001) in Participants with Unresectable or Metastatic Melanoma or Stage III or IV Non-Small-Cell Lung Cancer
Condition: Cutaneous
Intervention: IL-2 (Interleukin-2); IOV-4001 (); MESNA (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
CLINICAL TRIAL 22279
A phase 1a/b open-label master study of pf-07799544 as a Single-agent and in combination with other targeted agents In participants with braf-mutant melanoma and other solid Tumors
Condition: Cutaneous
Intervention: PF-07284890 (); PF-07799544 (); PF-0779993 (); PF-07799933 ()
CLINICAL TRIAL 22505
Cutaneous Adverse Events (irCAEs) Associated with Immunotherapy in Patients with Melanoma
Condition: Cutaneous
Intervention:
CLINICAL TRIAL 22536
Immune Profiling of Relatlimab and Nivolumab Combination Immunotherapy for Advanced Stage Metastatic Melanoma
Condition: Cutaneous
Intervention:
CLINICAL TRIAL 22554
A prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate efficacy, safety, and tolerability of IMA203 versus investigator's choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma (ACTengine® IMA203-301)
Condition: Cutaneous
Intervention: Albumin-Bound Paclitaxel (); BMS-936558 (Nivolumab); BMS-986016 (Relatlimab); DTIC (Dacarbazine); Dacarbazine (); IL-2 (Interleukin-2); IMA203 (); Ipilimumab (); Lifileucel (); Nivolumab (Opdivo); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Relatlimab (); Taxol (paclitaxel); Temodal (Temozolomide); Temozolomide (); Yervoy (Ipilimumab); carboplatin (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate); paclitaxel ()
CLINICAL TRIAL 22574
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); BMS-986016 (Relatlimab); Ipilimumab (); Nivolumab (Opdivo); Relatlimab (); Yervoy (Ipilimumab)
CLINICAL TRIAL 23082
Phase I/II Clinical Trial of CD40L-augmented Tumor Infiltrating Lymphocytes (TIL) for Patients with Advanced Melanoma
Condition: Cutaneous
Intervention: Aldesleukin (Interleukin-2); IL-2 (Interleukin-2); Interleukin-2 (); Proleukin (Interleukin-2); TIL (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
CLINICAL TRIAL 23318
Pembrolizumab for Advanced Cutaneous Sarcomas Not Including Angiosarcoma
Condition: Sarcoma
Intervention: Pembrolizumab (Keytruda)
CLINICAL TRIAL 23341
A Randomized, Controlled, Multicenter, Phase 3 Clinical Study Comparing Vusolimoqene Oderparepvec in Combination with Nivolumab Versus Treatment of Physician's Choice in Patients with Advanced Melanoma that Has Progressed on an Anti-PD-1 and an Anti-CTLA-4 Containing Treatment Regimen
Condition: Cutaneous
Intervention: Albumin-Bound Paclitaxel (); BMS-936558 (Nivolumab); BMS-986016 (Relatlimab); DTIC (Dacarbazine); Dacarbazine (); Nivolumab (Opdivo); Pembrolizumab (Keytruda); Relatlimab (); Taxol (paclitaxel); Temodal (Temozolomide); Temozolomide (); Vusolimogene Oderparepvec (); paclitaxel ()
CLINICAL TRIAL 23360
IFx-Hu2.0 as an Adjunctive Therapy to Pembrolizumab in Checkpoint Inhibitor Naïve Subjects with Advanced or Metastatic Merkel Cell Carcinoma
Condition: Cutaneous
Intervention: IFx-Hu2.0 (); Pembrolizumab (Keytruda)
CLINICAL TRIAL 23377
A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab versus Relatlimab and Nivolumab in Participants with Unresectable or Metastatic Melanoma.
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); BMS-986016 (Relatlimab); Cemiplimab (); Fianlimab (); Nivolumab (Opdivo); REGN2810 (Cemiplimab); Relatlimab ()
CLINICAL TRIAL 23474
A Multicenter, Open-Label, Randomized, Controlled Study to Assess the Antitumor Activity of LNS8801 With and Without Pembrolizumab in Patients With Treatment-Refractory, Unresectable Melanoma
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); BMS-986016 (Relatlimab); DTIC (Dacarbazine); Dacarbazine (); Ipilimumab (); LNS8801 (); Nivolumab (Opdivo); Pembrolizumab (Keytruda); Relatlimab (); Temodal (Temozolomide); Temozolomide (); Yervoy (Ipilimumab)
CLINICAL TRIAL 23475
A Phase 1/2 Study of OR502 Alone and in Combination with other Anti-cancer Agents in Subjects with Advanced Malignancies
Condition: Cutaneous
Intervention: Cemiplimab (); OR502 (); REGN2810 (Cemiplimab)
CLINICAL TRIAL 23597
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of IFx-Hu2.0 as an Adjunctive Therapy to Pembrolizumab in Checkpoint Inhibitor Naïve Participants with Advanced or Metastatic Merkel Cell Carcinoma
Condition: Cutaneous
Intervention: IFx-Hu2.0 (); Pembrolizumab (Keytruda); Placebo ()
CLINICAL TRIAL 23590
Randomized Phase III Trial of Neoadjuvant Immunotherapy with Response-Adapted Treatment versus Standard-Of-Care Treatment for Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma
Condition: Multiple
Intervention: Cemiplimab (); REGN2810 (Cemiplimab); Radiotherapy ()
CLINICAL TRIAL 23655
A Phase I/II, open-label, adaptive two-part trial to evaluate the safety, efficacy, optimal dose and pharmacokinetics of BNT326 as monotherapy and in combination with cancer immunotherapies in participants with advanced solid tumors
Condition: Cutaneous
Intervention: BNT326 (); BNT327 ()
CLINICAL TRIAL 23697
A Phase 1/1b, Open-label, Multicenter, First-in-human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of VVD-159642, a RAS-PI3KA Inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Condition: Multiple
Intervention: AMG 510 (Sotorasib); GSK1120212 (Trametinib); Olomorasib (); Sotorasib (); Trametinib (); VVD-159642 ()
CLINICAL TRIAL 23773
A Phase 1b/2 Study of AZD0120 (also known as GC012F), a Chimeric Antigen Receptor T Cell Therapy Targeting CD19 and B cell Maturation Antigen in Participants with Relapsed or Refractory AL Amyloidosis
Condition: Malignant Hematology
Intervention: AZD0120 ()
Treatment